On July 10, 2023 Alphamab Oncology (stock code: 9966.HK) reported that the phase Ⅱ clinical research results of anti- PD-L1/CTLA-4 bispecific antibody KN046 monotherapy in advanced NSCLC were published online in the European Journal of Cancer (EJC) (IF: 8.4001). Professor Caicun Zhou from Shanghai Pulmonary Hospital is the corresponding author of this paper.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
KN046-201 is an open-label, multi-center, multiple cohorts, single arm study to evaluate the efficacy, safety andtolerability of KN046 in NSCLC. Subjects with NSCLC who had failed from first line platinum-based doublet chemotherapy without PD-(L)1 immune checkpoint blockade were enrolled in cohort A and cohort B. All subjects enrolled will receive KN046 3 mg/kg (Cohort A) and 5mg/kg (Cohort B) Q2W IV administration, respectively. Primary endpoint was objective response rate (ORR) per RECIST version 1.1 by BICR.
All 64 patients were enrolled, 30 and 34 patients were included in the 3 mg/kg (cohort A) and 5 mg/kg (cohort B), respectively. On August 31, 2021, the median follow-up duration was 24.08 months and 19.35 months in the 3 mg/kg and 5 mg/kg cohorts, respectively. BICR-assessed ORRs were 13.3% and 14.7% in the 3 mg/kg and 5 mg/kg cohorts, respectively. Median progression-free survival (PFS) were 3.68 and 3.68 months, while overall survival (OS) were 19.70 and 13.04 months, respectively. Furthermore, the ORR was 17.1%, mPFS was 3.68 months and mOS was 19.81 months in non-squamous NSCLC (n=41). And in squamous NSCLC(n=20), the ORR was 10.0%, mPFS was 7.43 months and mOS was 12.88months.
All 64 enrolled patients were evaluable for safety, the most common treatment-related adverse events (TRAEs) were anemia (28.1%), hyperglycemia (26.7%), and infusion-related reactions (26.7%). The incidence rates of grade ≥3 TRAEs and TRAEs leading to treatment discontinuation were 42.2% and 14.1%, respectively.
Conclusion: Both 3 mg/kg and 5 mg/kg KN046 showed promising efficacy and favorable safety profile in advanced squamous and non-squamous NSCLC patients after failure of or intolerance to previous platinum-based chemotherapy. This study provided more basis for further development of KN046 in NSCL.
About KN046
KN046 is PD-L1/CTLA-4 bispecific antibody independently developed by Jiangsu Alphamab. Its innovative designs include: a novel mechanism – CTLA-4 fused with PD-L1 single domain antibody; engineered to target the tumor microenvironment with high PD-L1 expression, and Treg (suppress tumor immunity) clearing function.
There are about 20 clinical trials of KN046 in different stages covering more than 10 types of tumors including NSCLC, pancreatic cancer, thymic cancer, HCC, ESCC and TNBC in Australia, the US and China. The results of these clinical trials have shown an advantage in survival for patients. Alphamab Oncology has received FDA clearance to enter phase II trial of KN046 based on the clinical results in China and Australia. Moreover, KN046 has obtained the U.S. FDA’s orphan drug designation for thymic epithelial tumor in September 2020. Several pivotal clinical trials are currently being conducted, among which the interim analysis of the phase III clinical study of KN046 combined with chemotherapy as the first-line treatment of NSCLC successfully met the prespecified PFS endpoint.
(Press release, Alphamab, JUL 10, 2023, View Source [SID1234657025])